Asterias Biotherapeutics (NYSEAMERICAN:AST) has been given a $6.00 price objective by investment analysts at B. Riley in a research report issued on Thursday, March 1st. The brokerage presently has a “buy” rating on the biotechnology company’s stock. B. Riley’s target price indicates a potential upside of 242.86% from the company’s previous close. B. Riley also issued estimates for Asterias Biotherapeutics’ Q4 2017 earnings at ($0.18) EPS, FY2017 earnings at ($0.62) EPS, Q1 2018 earnings at ($0.16) EPS, Q2 2018 earnings at ($0.15) EPS, Q3 2018 earnings at ($0.16) EPS, Q4 2018 earnings at ($0.17) EPS, FY2018 earnings at ($0.64) EPS, FY2019 earnings at ($0.66) EPS, FY2020 earnings at ($0.70) EPS, FY2021 earnings at ($0.75) EPS and FY2022 earnings at ($0.19) EPS.
AST has been the subject of several other research reports. Zacks Investment Research downgraded Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 22nd. HC Wainwright set a $11.00 price target on Asterias Biotherapeutics and gave the stock a “buy” rating in a research report on Monday, January 8th. Two investment analysts have rated the stock with a sell rating and three have issued a buy rating to the company. Asterias Biotherapeutics presently has an average rating of “Hold” and an average target price of $7.94.
Asterias Biotherapeutics stock traded down $0.15 during trading on Thursday, reaching $1.75. The company’s stock had a trading volume of 175,222 shares, compared to its average volume of 231,488. The stock has a market capitalization of $102.89, a P/E ratio of -2.69 and a beta of 1.02. Asterias Biotherapeutics has a one year low of $1.65 and a one year high of $4.30.
COPYRIGHT VIOLATION WARNING: “Asterias Biotherapeutics (AST) PT Set at $6.00 by B. Riley” was originally reported by BBNS and is owned by of BBNS. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://baseballnewssource.com/2018/03/26/asterias-biotherapeutics-ast-given-a-6-00-price-target-by-b-riley-analysts/1953452.html.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.